Information Provided By:
Fly News Breaks for November 29, 2016
NVLS
Nov 29, 2016 | 07:05 EDT
As noted earlier, Stifel downgraded Nivalis to Hold from Buy. Analyst Thomas Shrader downgraded the stock after the company's cavosonstat for CF did not show meaningful efficacy in a Phase II trial. Target to $3.25 from $16.
News For NVLS From the Last 2 Days
There are no results for your query NVLS